Zai Lab
Open
$17.78
Prev. Close
$17.79
High
$17.80
Low
$17.73
Market Snapshot
$1.96B
-11.0
-2.50
$398.99M
Zai Lab Ltd. is a biopharmaceutical company, which engages in the developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders, infectious diseases, and neuroscience. The firm is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The firm has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The firm conducts its businesses within domestic and overseas markets.
Zai Lab's recent approval of TIVDAK highlights potential growth opportunities in oncology, positioning the company favorably despite recent challenges in the market.
Zai Lab Ltd. is a biopharmaceutical company, which engages in the developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders, infectious diseases, and neuroscience. The firm is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The firm has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The firm conducts its businesses within domestic and overseas markets.
Recently from Cashu
Zai Lab Advances Oncology and Immunology Pipelines with Promising Clinical Updates
Zai Lab, a growing force in the pharmaceutical sector, unveils significant advancements in its clinical and preclinical pipelines. This development underscores the company’s potential impact in areas…
Zai Lab and Amgen Collaborate on Global Lung Cancer Clinical Trial
Zai Lab Limited announces a strategic collaboration with Amgen Inc. that aims to enhance treatment options for patients suffering from extensive-stage small cell lung cancer (SCLC). This partnership i…
Zai Lab Reports Strong Earnings Growth and Strategic Focus on Biopharmaceutical Innovation
Zai Lab's Strategic Shift in Biopharmaceuticals: A Bright Future Ahead Zai Lab (NASDAQ: ZLAB) demonstrates a significant upward trajectory in its latest quarterly earnings report, released on February…
Zai Lab Reports Q4 Earnings Growth and Strengthens Biopharma Pipeline Strategy
Zai Lab’s Q4 Earnings Showcase Growth in Biopharma Pipeline Zai Lab, a biopharmaceutical company specializing in oncology and autoimmune diseases, recently announces its Q4 earnings for 2026, demonstr…